BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines' Memorial Club in San Francisco, Californi ...

"This is a story about how a tool can be used to try to affect politics and in particular to minimize women, denigrate them and push them out of the conversation.†...

TORONTO, Jan. 9, 2026 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS") industry, today announced that its management team will present virtually at the th28 Annual Needham Growth Conference, highlighting continued execution across its operational transformation and expanding global ITS footprint. Quarterhill CEO Chuck Myers and CFO David Charron are scheduled ...

It could be the year Main Street's appetite for cryptocurrency exposure meaningfully grows.Although it's been two years since the first spot bitcoin ETFs began trading on U.S. exchanges, BlackRock's Jay Jacobs thinks they're a fairly new concept."It's still so early," the firm's U.S. head of equity ETFs told CNBC's "ETF Edge" this week. "Many investors have still just been starting their educational journey around what is bitcoin, [and] how might it fit in a portfolio .… We see this still being very early d ...

Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is ongoing and no final FDA decision has been madeProgresses global regulatory expansion activities in Canada, Europe, and the United Kingdom for AnaphylmUnaudited cash and cash equivalents of approximately $120 million as of December 31, 2025 WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aquestiv ...

SHENZHEN, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it has entered into a strategic partnership with Xiaoe Inc. (“Xiaoe”) to integrate its intelligent push notification solution, JPush, into Xiaoe’s flagship private domain SaaS platform. When operating private domains, a platform’s value lies not only in providing operational tools b ...

New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovationBOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Company’s transfo ...

IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- iHerb Holdings, LLC, one of the world’s largest online retailers specializing in health and wellness, today announced that it has completed its acquisition of Vitacost.com, Inc. (“Vitacost”) from The Kroger Co. (“Kroger”). This acquisition is expected to significantly accelerate iHerb’s market presence in the U.S. and firmly establish the combined entity as a top online destination for health, nutrition and wellness products. Vitacost: A Trusted Name in Well ...

Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior ...

®— BRINSUPRI (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— ®—ARIKAYCE (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with Unaudited Global Revenues of Approximately $433.8 Million— —Full-Year 2026 Global ARIKAYCE Revenues Expected to be Between $450 Million and $470 Million— —Topline Data from Phase 3 ENCORE Study of ARIKAYCE in Patients with Newly ...